We'd like your feedback
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.
Anthony
Maraveyas
anthony.maraveyas@nhs.net
Laura
Broughton
Laura.Broughton@hull.ac.uk
Malignant neoplasms of digestive organs
This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.
Pancreatic cancer is difficult to diagnose early as it does not usually cause any signs or symptoms in these early stages. Once it reaches a more advanced stage,it is very difficult to treat and survival is poor. Diagnosing pancreatic cancer often requires a number of different tests,some of which can be invasive and uncomfortable. A non-invasive test capable of detecting pancreatic cancer in its earliest stages would therefore increase chances of survival and improve patient quality of life. Cysts found in the pancreas are often not cancerous,but on occasions are found to develop into pancreatic cancer. Detecting changes in these cysts before a cancer develops may provide a good way to detect cancer early.
We intend to use new laboratory tests that measure the levels of different proteins and also the changes in genes in blood,urine and cystic fluid samples. Initial studies in common cancers such as in breast,prostate and colon have shown promise for these protein-based or gene-based techniques to detect changes in cells that indicate early stages of development of a cancer. So we now intend to see if these tests are also effective in early detection of pancreatic cancer. In this study,these proteins will be measured in urine,blood and,where available,cystic fluid samples from patients diagnosed with cancer,or having investigations for pancreatic cysts,to determine whether they can serve as markers for early pancreatic cancer.
Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.
The recruitment start and end dates are as follows:
Observational type: Cohort study;
You can take part if:
You may not be able to take part if:
General: 1. Inability to provide written informed consent. 2. Other known malignant condition,either active or in complete remission ≤5 years. 3. HIV,hepatitis C,or any other known communicable disease.
Below are the locations for where you can take part in the trial. Please note that not all sites may be open.
The study is sponsored by HULL UNIVERSITY TEACHING HOSPITALS NHS TRUST and funded by CANCER RESEARCH UK; HULL UNIVERSITY TEACHING HOSPITALS NHS TRUST; University of Hull; .
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Read full details
for Trial ID: CPMS 55297
You can print or share the study information with your GP/healthcare provider or contact the research team directly.
